Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Unknown 25Completed 14Terminated 3Recruiting 2Not yet recruiting 2Available 1Active not recruiting 1

Sponsor Class

OTHER 49OTHER_GOV 2INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Tumor-Agnostic 1Sarcoma 1

Conditions

Sarcoma 1Osteosarcoma 1Neoplasm Metastasis 1

Interventions

Injections 39Carboplatin 33Capecitabine 24Paclitaxel 23Cisplatin 23Docetaxel 22pembrolizumab 21Oxaliplatin 21Gemcitabine 21Bevacizumab 19Pemetrexed 18Fluorouracil 13Irinotecan 12Cyclophosphamide 11osimertinib 9Nivolumab 9Dexamethasone 8Topotecan 7Leucovorin 7130-nm albumin-bound paclitaxel 7venetoclax 6toripalimab 6tislelizumab 6regorafenib 6lenvatinib 6fludarabine 6Doxorubicin 6Cetuximab 6daratumumab 5atezolizumab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Not yet recruiting × INDUSTRY × anlotinib × Clear all
NCT07562581 2026-05-01

A Phase 2 Study of Luvometinib Combined With Anlotinib in KRAS-mutated NSCLC

Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.

Phase 2 Not yet recruiting
48 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT06699576 2024-11-21

ARTEMIS-103: Phase 1b Study of HS-20093 Combinations in Patients with Bone and Soft Tissue Sarcoma.

Hansoh BioMedical R&D Company

Phase 1 Not yet recruiting
448 enrolled
Sarcoma

Sarcoma, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡